Last Updated: November 16, 2026

Investigational Drug Information for Defactinib

« Back to Dashboard


What is the development status for investigational drug Defactinib?

Defactinib is an investigational drug.

There have been 35 clinical trials for Defactinib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 29th 2024.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Pancreatic Neoplasms. The leading clinical trial sponsors are Verastem, Inc., National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.

There are two hundred and eighteen US patents protecting this investigational drug and four hundred and sixty-five international patents.

Recent Clinical Trials for Defactinib
TitleSponsorPhase
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerVerastem, Inc.PHASE1
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerM.D. Anderson Cancer CenterPHASE1
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaThe Foundation for Barnes-Jewish HospitalPHASE2

See all Defactinib clinical trials

Clinical Trial Summary for Defactinib

Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib

See all Defactinib clinical trials

US Patents for Defactinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Defactinib ⤷  Start Trial Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Start Trial
Defactinib ⤷  Start Trial Gene fusions and gene variants associated with cancer LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA) ⤷  Start Trial
Defactinib ⤷  Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Start Trial
Defactinib ⤷  Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Defactinib

Drugname Country Document Number Estimated Expiration Related US Patent
Defactinib Australia AU2011261185 2030-06-03 ⤷  Start Trial
Defactinib Australia AU2015275321 2030-06-03 ⤷  Start Trial
Defactinib Australia AU2018204179 2030-06-03 ⤷  Start Trial
Defactinib Australia AU2020202752 2030-06-03 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.